Compare Aurobindo Pharma with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs JUBILANT LIFE SCIENCES - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA JUBILANT LIFE SCIENCES AUROBINDO PHARMA/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 11.0 14.3 76.7% View Chart
P/BV x 2.4 1.7 142.6% View Chart
Dividend Yield % 0.5 0.9 58.9%  

Financials

 AUROBINDO PHARMA   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
JUBILANT LIFE SCIENCES
Mar-19
AUROBINDO PHARMA/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs809898 90.1%   
Low Rs504618 81.6%   
Sales per share (Unadj.) Rs281.1572.0 49.1%  
Earnings per share (Unadj.) Rs41.436.2 114.2%  
Cash flow per share (Unadj.) Rs50.959.5 85.5%  
Dividends per share (Unadj.) Rs2.504.50 55.6%  
Dividend yield (eoy) %0.40.6 64.1%  
Book value per share (Unadj.) Rs199.4301.9 66.0%  
Shares outstanding (eoy) m585.88159.28 367.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.31.3 176.3%   
Avg P/E ratio x15.920.9 75.9%  
P/CF ratio (eoy) x12.912.7 101.3%  
Price / Book Value ratio x3.32.5 131.2%  
Dividend payout %6.012.4 48.7%   
Avg Mkt Cap Rs m384,630120,694 318.7%   
No. of employees `00017.32.4 725.2%   
Total wages/salary Rs m21,30819,260 110.6%   
Avg. sales/employee Rs Th9,500.738,120.6 24.9%   
Avg. wages/employee Rs Th1,229.48,058.4 15.3%   
Avg. net profit/employee Rs Th1,397.92,414.3 57.9%   
INCOME DATA
Net Sales Rs m164,66691,108 180.7%  
Other income Rs m1,020357 285.3%   
Total revenues Rs m165,68691,466 181.1%   
Gross profit Rs m37,71817,390 216.9%  
Depreciation Rs m5,5803,709 150.4%   
Interest Rs m7772,198 35.4%   
Profit before tax Rs m32,38011,840 273.5%   
Minority Interest Rs m310-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-2,802 0.0%   
Tax Rs m8,1833,268 250.4%   
Profit after tax Rs m24,2295,770 419.9%  
Gross profit margin %22.919.1 120.0%  
Effective tax rate %25.327.6 91.6%   
Net profit margin %14.76.3 232.3%  
BALANCE SHEET DATA
Current assets Rs m121,87845,848 265.8%   
Current liabilities Rs m86,80620,897 415.4%   
Net working cap to sales %21.327.4 77.8%  
Current ratio x1.42.2 64.0%  
Inventory Days Days13057 228.7%  
Debtors Days Days6851 134.2%  
Net fixed assets Rs m81,03765,498 123.7%   
Share capital Rs m586159 367.8%   
"Free" reserves Rs m116,21847,930 242.5%   
Net worth Rs m116,80448,089 242.9%   
Long term debt Rs m4,51242,429 10.6%   
Total assets Rs m211,052114,685 184.0%  
Interest coverage x42.76.4 668.0%   
Debt to equity ratio x00.9 4.4%  
Sales to assets ratio x0.80.8 98.2%   
Return on assets %11.86.9 170.5%  
Return on equity %20.712.0 172.9%  
Return on capital %27.412.4 220.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m80,72712,422 649.9%   
Fx outflow Rs m34,70017,227 201.4%   
Net fx Rs m46,027-4,805 -957.9%   
CASH FLOW
From Operations Rs m19,54811,215 174.3%  
From Investments Rs m-19,570-10,118 193.4%  
From Financial Activity Rs m8,6426,574 131.4%  
Net Cashflow Rs m8,9227,612 117.2%  

Share Holding

Indian Promoters % 54.1 45.6 118.6%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 8.0 8.7 91.4%  
FIIs % 27.7 21.2 130.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 21.1 48.3%  
Shareholders   69,601 23,815 292.3%  
Pledged promoter(s) holding % 8.6 15.9 54.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   FDC LTD.  UNICHEM LAB  WYETH LTD  AJANTA PHARMA  ALEMBIC LTD  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Oct 18, 2019 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS